Agios Pharmaceuticals closed its second quarter with the commercial engine finally in motion and a single federal decision hanging over everything it does next. The engine: mitapivat, sold in the United States as AQVESME for thalassemia and abroad as PYRUKYND, delivered $44.7 million of net product revenue in the quarter - more than three times the year-ago $12.5 million, and more than double the $20.7 million the first quarter produced. The launch is not just accelerating; it is compounding on itself, with 442 cumulative AQVESME prescriptions written by U.S. physicians as of June 30. The decision: the FDA has accepted Agios' supplemental application for mitapivat in sickle cell disease under Priority Review, with a PDUFA goal date of November 1, 2026 - a judgment that, if favorable, would hand the company a second, far larger commercial indication before year-end.
The quarter's numbers tell the same two-part story. Revenue inflecting up at a steep clip, but the profit line nowhere in sight. Net loss narrowed to $100.7 million for the quarter from $112.0 million a year earlier, and $199.8 million for the first half, held in check only because revenue is rising faster than the R&D and commercial spend needed to chase it. Management poured $100.8 million into research and development in the quarter, including the $25.0 million up-front payment to license cevidoplenib, a next-generation spleen tyrosine kinase inhibitor for immune thrombocytopenia - the clearest sign yet that Agios is deliberately buying its way out of single-product dependency. Against that spending sits $964.8 million of cash, cash equivalents and marketable securities. The thesis is a bet on a decision: at roughly $32.69, the market has already begun to pay a premium for the sickle cell option, but the real re-rating - for better or worse - is still locked to a calendar date eight weeks out.